{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:25:19Z","timestamp":1780446319506,"version":"3.54.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:p>This study employs CiteSpace software to analyze the research status, hotspots, and trends of primary Sjogren syndrome (pSS). Relevant publications from 1999 to 2023 were searched in the Web of Science Core Collection (WoSCC) set, followed by generating a network map using CiteSpace software to identify top authors, institutions, countries, keywords, journals, references, and research trends. A total of 3564 valid articles were included in this study. The People Republic of China had the highest number of articles (n\u2005=\u2005524), while the University of Bergen emerged as the institution with the highest publication count (n\u2005=\u200594). Mariette X was identified as the author with the most publications (n\u2005=\u200567), whereas Vitali C received recognition as the most cited author (n\u2005=\u20051706). Annals of Rheumatic Diseases stood out as the journal with the highest citation count (n\u2005=\u20052530). Notably, an article published in the Annals of Rheumatic Diseases in 2017 garnered significant attention by being cited a remarkable 304 times. The bibliometric analysis reveals that key areas of research in pSS encompass investigating pathogenesis; advancing and applying targeted biological agents; and establishing treatment and diagnostic standards.<\/jats:p>","DOI":"10.1097\/md.0000000000038162","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:06:59Z","timestamp":1718388419000},"page":"e38162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Primary Sjogren syndrome \u2013 A bibliometric analysis via CiteSpace"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8771-0171","authenticated-orcid":false,"given":"Mingrui","family":"Yang","sequence":"first","affiliation":[{"name":"School of pharmacy, Shandong University of Traditional Chinese Medicine, Ji\u2019nan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhi","family":"Wang","sequence":"additional","affiliation":[{"name":"School of pharmacy, Shandong University of Traditional Chinese Medicine, Ji\u2019nan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of pharmacy, Shandong University of Traditional Chinese Medicine, Ji\u2019nan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-0633","authenticated-orcid":false,"given":"Bin","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Traditional of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji\u2019nan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.medcli.2022.10.007","article-title":"Sj\u00f6gren syndrome. S\u00edndrome de Sjogren.","volume":"160","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"R2-20250503","first-page":"354","article-title":"The diagnosis and treatment of Sjogren\u2019s syndrome.","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.coms.2013.09.001","article-title":"Diagnosis of Sjogren\u2019s syndrome: American-European and the American College of Rheumatology classification criteria.","volume":"26","author":"Sankar","year":"2014","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4140\/TCP.n.2018.691.","article-title":"Management of primary Sjogren\u2019s syndrome.","volume":"33","author":"Marshall","year":"2018","journal-title":"Consult Pharm"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European league against rheumatism classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts.","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren\u2019s syndrome.","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"797902","DOI":"10.3389\/fmolb.2021.797902","article-title":"Molecular mechanisms of exercise on cancer: a bibliometrics study and visualization analysis via CiteSpace.","volume":"8","author":"Zhong","year":"2022","journal-title":"Front Mol Biosci"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/14712598.2014.920813","article-title":"Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014).","volume":"14","author":"Chen","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sjogren\u2019s syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment.","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1756-185X.13839","article-title":"Update on disease pathogenesis, diagnosis, and management of primary Sjogren\u2019s syndrome.","volume":"23","author":"Wang","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R12-20250503","first-page":"3","article-title":"One year in review 2020: pathogenesis of primary Sjogren\u2019s syndrome.","volume":"38 Suppl 126","author":"Bombardieri","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/13543784.2019.1631796","article-title":"Small-molecule inhibitors and the salivary gland epithelium in Sjogren\u2019s syndrome.","volume":"28","author":"Pringle","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl Suppl 1","key":"R14-20250503","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/eos.12536","article-title":"Current concepts on Sjogren\u2019s Syndrome - classification criteria and biomarkers.","volume":"126 Suppl 1","author":"Jonsson","year":"2018","journal-title":"Eur J Oral Sci"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sjogren\u2019s syndrome: a systemic autoimmune disease.","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin Exp Med"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.survophthal.2019.10.004","article-title":"Primary Sjogren\u2019s syndrome and the eye.","volume":"65","author":"Bjordal","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"R17-20250503","first-page":"301","article-title":"Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjogren\u2019s syndrome.","volume":"38 Suppl 126","author":"Vehof","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1196\/annals.1384.003","article-title":"Autoimmune diseases and Sjogren\u2019s syndrome: an autoimmune exocrinopathy.","volume":"1098","author":"Fox","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/rheumatology\/keaa017","article-title":"Vaginal dryness in primary Sjogren\u2019s syndrome: a histopathological case-control study.","volume":"59","author":"van Nimwegen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.berh.2015.05.002","article-title":"Pain in primary Sjogren\u2019s syndrome.","volume":"29","author":"Vitali","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1007\/s10067-021-05656-0","article-title":"Juvenile primary Sjogren\u2019s syndrome with cutaneous involvement.","volume":"40","author":"He","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R22-20250503","first-page":"110","article-title":"Digestive involvement in primary Sjogren\u2019s syndrome: analysis from the Sj\u00f6grenser registry.","volume":"38 Suppl 126","author":"Melchor","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R23-20250503","first-page":"697","article-title":"Autonomic nervous system dysfunction involving the gastrointestinal and the urinary tracts in primary Sjogren\u2019s syndrome.","volume":"21","author":"Kov\u00e1cs","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"592","DOI":"10.46497\/ArchRheumatol.2020.7427","article-title":"Evaluation of asymptomatic bacteriuria and urinary tract infection in patients with primary Sjogren\u2019s syndrome.","volume":"35","author":"\u00c7etin","year":"2020","journal-title":"Arch Rheumatol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-020-2118-1","article-title":"Seasonal effect on fatigue, pain and dryness in primary Sjogren\u2019s syndrome.","volume":"22","author":"Duret","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"Suppl Suppl 1","key":"R26-20250503","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/eos.12536","article-title":"Current concepts on Sjogren\u2019s syndrome - classification criteria and biomarkers.","volume":"126 Suppl 1","author":"Jonsson","year":"2018","journal-title":"Eur J Oral Sci"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/jcm12062428","article-title":"Diagnostic evaluation using salivary gland ultrasonography in primary Sjogren\u2019s syndrome.","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1093\/rheumatology\/kez079","article-title":"Salivary gland ultrasonography in primary Sjogren\u2019s Syndrome: opportunities and challenges.","volume":"60","author":"Devauchelle-Pensec","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sjogren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling.","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2018.09.003","article-title":"Novel autoantibodies in Sjogren\u2019s syndrome: a comprehensive review.","volume":"18","author":"Mart\u00edn-Nares","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R31-20250503","first-page":"119","article-title":"Efficacia di Carbopol 974P (Siccafluid) nel trattamento della cheratocongiuntivite sicca di grado moderato-severo in 60 casi con S. di Sj\u00f6gren primitiva [Efficacy of Carbopol 974P (Siccafluid) in the treatment of severe to moderate keratoconjunctivitis sicca in patients with primary Sjogren\u2019s syndrome not responding to standard treatment with artificial tears].","volume":"57","author":"Ostuni","year":"2005","journal-title":"Reumatismo"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","article-title":"Punctal plugs versus artificial tears for treating primary Sjogren\u2019s syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function.","volume":"33","author":"Qiu","year":"2013","journal-title":"Rheumatol Int"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.reuma.2015.03.010","article-title":"Oral involvement in patients with primary Sjogren\u2019s syndrome. Multidisciplinary care by dentists and rheumatologists.","volume":"11","author":"L\u00f3pez-Pintor","year":"2015","journal-title":"Reumatol Clin"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sjogren\u2019s Syndrome patients.","volume":"40","author":"Jiang","year":"2020","journal-title":"Int Ophthalmol"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"356040","DOI":"10.1155\/2015\/356040","article-title":"Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis.","volume":"2015","author":"Xu","year":"2015","journal-title":"Mediators Inflamm"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10067-017-3822-3","article-title":"Primary Sjogren\u2019s syndrome: extraglandular manifestations and hydroxychloroquine therapy.","volume":"36","author":"Demarchi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"e12476","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond.","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"693796","DOI":"10.3389\/fphar.2021.693796","article-title":"The efficiency of hydroxychloroquine for the treatment of primary Sjogren\u2019s syndrome: a systematic review and meta-analysis.","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome.","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.berh.2020.101485","article-title":"Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjogren\u2019s syndrome.","volume":"34","author":"van den Hoogen","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies.","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"731122","DOI":"10.3389\/fphar.2021.731122","article-title":"Rituximab therapy for primary Sjogren\u2019s syndrome.","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/imt-2021-0174","article-title":"Immunoregulatory effects of dental mesenchymal stem cells on T and B lymphocyte responses in primary Sjogren\u2019s Syndrome.","volume":"14","author":"Gen\u00e7","year":"2022","journal-title":"Immunotherapy"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s10787-023-01189-x","article-title":"Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4+ T cells in patients with primary Sjogren\u2019s syndrome.","volume":"31","author":"Ma","year":"2023","journal-title":"Inflammopharmacology"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"4357865","DOI":"10.1155\/2018\/4357865","article-title":"Mesenchymal stem cells in primary Sjogren\u2019s syndrome: prospective and challenges.","volume":"2018","author":"Chen","year":"2018","journal-title":"Stem Cells Int"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00018-017-2473-5","article-title":"Interactions between mesenchymal stem cells and the immune system.","volume":"74","author":"Li","year":"2017","journal-title":"Cell Mol Life Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:40:24Z","timestamp":1746319224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":46,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038162","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}